<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/tarsus-pharmaceuticals-acquires-alkeus-pharmaceuticals-alk-001-stargardt</loc>
    <lastmod>2026-09-04T22:18:32+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>Tarsus Acquires Alkeus, Adds Phase 3 Stargardt Drug</news:title>
      <news:keywords>Tarsus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/f48f05bc-2c0d-47e1-bb45-c5c3bd586fe6/072421b7-6f12-4d89-abaa-c38a174b481d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/peptides-complex-generics-symposium-2026-returns-to-mumbai</loc>
    <lastmod>2026-09-04T18:24:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T18:24:38+05:30</news:publication_date>
      <news:title>Peptides &amp; Complex Generics Symposium 2026 Returns to Mumbai</news:title>
      <news:keywords>Peptides &amp; Complex Generics Symposium 2026, 
PCG 2026, 
peptide therapeutics, 
complex generics,</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/image(1)20260904181315.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/agilent-launches-icp-ms-gc-systems-digital-lab-platform-india</loc>
    <lastmod>2026-09-04T10:46:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>Agilent Launches ICP-MS, GC Systems and Digital Lab Platform</news:title>
      <news:keywords>Agilent</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/23279db7-e1c8-41de-abf4-2f3901c83fc3/70e0237d-c086-43bf-8960-5e8af717b7be.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cohance-lifesciences-18-million-nj-bio-aruka-bio-adc-manufacturing</loc>
    <lastmod>2026-09-04T10:46:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>Cohance Lifesciences Secures $18M Stake in NJ &amp; Aruka Bio</news:title>
      <news:keywords>Cohance Lifesciences</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/23279db7-e1c8-41de-abf4-2f3901c83fc3/528c1cec-f162-4b87-92e4-11f2a017005e.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/rpg-life-sciences-acquires-raghava-life-sciences-api-business</loc>
    <lastmod>2026-09-04T10:46:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>RPG Life Sciences Acquires Raghava Life Sciences API Business</news:title>
      <news:keywords>RPG Life Sciences</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/23279db7-e1c8-41de-abf4-2f3901c83fc3/2542da71-85c2-4487-9fcd-37cbb2880110.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/american-regent-epinephrine-recall-particulate-sterility-2026</loc>
    <lastmod>2026-09-04T10:46:29+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>American Regent Recalls Three Epinephrine Lots Over Cracked Vials</news:title>
      <news:keywords>American Regent</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/23279db7-e1c8-41de-abf4-2f3901c83fc3/fa50f240-e3fa-4a9d-9e36-2b2a13e6ee98.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/axcelead-fda-nams-road-map-seminar-ind-submission-strategy</loc>
    <lastmod>2026-09-04T10:47:55+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>Axcelead Releases FDA NAMs Road Map Seminar on IND Strategy</news:title>
      <news:keywords>Axcelead</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://axcelead-us.com/wp-content/uploads/2026/09/20260904-Webinar-TIM-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cipla-invagen-qilu-keytruda-biosimilar-us-deal</loc>
    <lastmod>2026-09-04T10:46:33+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>Cipla InvaGen Signs Biosimilar Deal with Qilu for US Market</news:title>
      <news:keywords>Cipla</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/23279db7-e1c8-41de-abf4-2f3901c83fc3/b0b615a9-a8e7-4fe5-8c61-21a1df9d210f.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/pendopharm-cda-amc-conditional-reimbursement-yorvipath-chronic-hypoparathyroidism</loc>
    <lastmod>2026-09-04T10:51:05+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>Pendopharm Secures AMC Reimbursement Nod for Yorvipath</news:title>
      <news:keywords>Pendopharm</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/54fc8afb-c164-4d78-93f3-dff346091b3b/49f0e6be-51c7-46e6-a0c3-f7cc62dd8387.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cber-regulatory-framework-allergenic-products-biologics</loc>
    <lastmod>2026-09-04T10:56:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>CBER Maintains Framework for Three Allergenic Products</news:title>
      <news:keywords>CBER</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/54fc8afb-c164-4d78-93f3-dff346091b3b/4f2d8a80-67b8-4482-b441-0eda2b02799a.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-approves-zanvastro-first-treatment-alexander-disease</loc>
    <lastmod>2026-09-04T10:57:04+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-04T00:00:00+05:30</news:publication_date>
      <news:title>FDA Approves Zanvastro as First Treatment for Alexander Disease</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/54fc8afb-c164-4d78-93f3-dff346091b3b/c79a4398-47ea-4071-b04a-2dad7c6a2d76.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-estradiol-transdermal-patch-supply-shortfall-2026</loc>
    <lastmod>2026-09-04T17:22:25+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>FDA Works With Six Manufacturers to Ease Estradiol Patch Shortage</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda_estradiol_transdermal_patch_supply_shortfall20260904172118.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-ema-joint-workshop-botanical-drug-development-2026</loc>
    <lastmod>2026-09-04T18:01:12+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>FDA and EMA Join Forces on Botanical Drug Development</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda_ema_joint_workshop_botanical_drug_development_202620260904180101.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-2026-2027-influenza-vaccine-strain-recommendations</loc>
    <lastmod>2026-09-04T18:06:18+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>FDA Finalizes 2026–2027 Flu Vaccine Strain Selection</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/influenza_virus_flu_vaccine_vial_fda_2026_2027_strain_recommendations20260904180545.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-acquires-apogee-therapeutics-10-9b-half-life-extended-antibody-pipeline</loc>
    <lastmod>2026-09-04T18:14:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Acquires Apogee Therapeutics for Half-Life Extended Antibody Pipeline</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie_logo_acquires_apogee_therapeutics_10_9b_antibody_pipeline20260904181428.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fibrobiologics-secures-us-patent-3d-spheroid-fibroblast-wound-healing</loc>
    <lastmod>2026-09-04T18:20:17+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>FibroBiologics Secures U.S. Patent for 3D Spheroid Fibroblast Wound Healing Therapy</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fibrobiologics_logo_us_patent_3d_spheroid_fibroblast_wound_healing20260904181822.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-phase-3-cervino-trial-etentamig-rrmm-results-2026</loc>
    <lastmod>2026-09-04T18:43:46+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie’s Etentamig Meets Dual Endpoints in Phase 3 Myeloma Trial</news:title>
      <news:keywords>AbbVie’</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie_headquarters_building_phase_3_cervino_trial_etentamig_rrmm_202620260904184329.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cellipont-bioservices-texas-facility-six-ind-submissions-2026</loc>
    <lastmod>2026-09-04T18:49:27+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>Cellipont Texas Facility Supports Six 2026 IND Programs</news:title>
      <news:keywords>Cellipont</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cellipont_bioservices_facility_texas_six_ind_submissions_202620260904184742.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/eledon-pharmaceuticals-islet-cell-ind-tegoprubart-transplant-programs-2026</loc>
    <lastmod>2026-09-03T22:11:32+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>Eledon Submits Islet Cell IND for Tegoprubart</news:title>
      <news:keywords>Eledon</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/79280130-d192-4773-a188-a686cd3ad144/c17d9b38-7ba9-4958-88dc-9a7972fffe29.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/wuxi-apptec-extrahepatic-oligonucleotide-delivery-cdmo-manufacturing</loc>
    <lastmod>2026-09-03T22:18:07+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>WuXi AppTec Explores CDMO Shifts in Oligonucleotide Delivery</news:title>
      <news:keywords>WuXi</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/79280130-d192-4773-a188-a686cd3ad144/627ae22e-2a03-4056-add4-39143fe7b7e2.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/inventiva-completes-last-patient-visit-nativ3-phase-3-lanifibranor-mash</loc>
    <lastmod>2026-09-03T10:27:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>Inventiva Completes Last Patient Visit in NATiV3 Phase 3 Trial</news:title>
      <news:keywords>Inventiva</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/2c2915a6-9bb2-4de2-b3b9-3c9a9a35504a/0acf9cd9-7c60-49f6-85f5-0b8a5a383226.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/pfizer-biontech-covid-19-eua-revoked-comirnaty-bla-manufacturing-controls</loc>
    <lastmod>2026-09-03T10:23:06+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>Pfizer COVID-19 Vaccine EUA Revoked; Comirnaty BLA Takes Effect</news:title>
      <news:keywords>Pfizer</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/2c2915a6-9bb2-4de2-b3b9-3c9a9a35504a/f7b07337-fddf-4a91-9a74-8d72ddb874f8.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/moderna-spikevax-eua-revocation-bla-approval-fda-2025</loc>
    <lastmod>2026-09-03T10:26:17+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>Moderna Loses EUA Status as Spikevax Gains Full FDA Approval</news:title>
      <news:keywords>Moderna</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/2c2915a6-9bb2-4de2-b3b9-3c9a9a35504a/cea1b0eb-5453-4fe7-8f20-ac7e2f97cb5d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-standard-safety-tables-figures-nda-bla-review-framework</loc>
    <lastmod>2026-09-03T10:20:48+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>FDA Issues Safety Tables &amp; Figures Framework for NDA/BLA Reviews</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/8282a666-d316-4b32-9efd-294f94386135/5e161d7f-3683-4c6e-b944-25da97352b57.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-gcp-enforcement-foreign-clinical-trial-sites-inspection-risk</loc>
    <lastmod>2026-09-03T10:20:54+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-03T00:00:00+05:30</news:publication_date>
      <news:title>FDA Signals GCP Shift as Foreign Trial Sites Face Inspections</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/8282a666-d316-4b32-9efd-294f94386135/64ad42f1-0149-434e-a0c6-f839cc3a7aee.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/india-glycols-demerges-biopharma-ennature-bio-pharma-limited</loc>
    <lastmod>2026-09-02T22:12:00+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>India Glycols Demerges Biopharma Unit Into Ennature Bio Pharma</news:title>
      <news:keywords>India</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/22aad319-4a98-4823-8a1a-a5786824cf82/1cd81ef6-fdbf-45b1-8550-e72924e03df4.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/neurothera-labs-fda-orphan-drug-designation-sci-110-adult-tourette-syndrome</loc>
    <lastmod>2026-09-02T22:11:04+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>NeuroThera Seeks FDA Orphan Drug Status for SCI-110</news:title>
      <news:keywords>NeuroThera</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/22aad319-4a98-4823-8a1a-a5786824cf82/d3b03631-f3d5-4974-9aaa-0479f8789828.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-hepatic-impairment-pk-study-design-labeling-guidance-2026</loc>
    <lastmod>2026-09-02T22:09:17+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates Guidance on Hepatic Impairment PK Studies</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/22aad319-4a98-4823-8a1a-a5786824cf82/084833bb-be91-4ebf-87bb-7e025ed76385.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novartis-suspends-rap-cel-autoimmune-trials-iec-hs-deaths</loc>
    <lastmod>2026-09-02T22:05:58+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>Novartis Halts Rap-cel Trials After Three Patient Deaths</news:title>
      <news:keywords>Novartis</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/22aad319-4a98-4823-8a1a-a5786824cf82/97b6e7ce-d836-4dd3-a1b0-f60ff58c9638.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/teva-trump-administration-medicaid-drug-costs-deal</loc>
    <lastmod>2026-09-02T22:04:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>Teva Nears Trump Administration Deal to Cut Medicaid Drug Costs</news:title>
      <news:keywords>Teva</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/efaa96cf-a16b-4a06-9d94-7b8e13e66680/0e9bfa02-d51c-4758-a417-f5b41673f85a.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/astrazeneca-acquires-dizal-pharma-zegfrovy-lung-cancer</loc>
    <lastmod>2026-09-02T22:02:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>AstraZeneca Acquires Dizal, Secures Global Zegfrovy Rights</news:title>
      <news:keywords>AstraZeneca</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/efaa96cf-a16b-4a06-9d94-7b8e13e66680/01462965-e6e3-4985-80de-77b1278c4ec5.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/teva-tev-408-phase-2a-celiac-disease-primary-endpoint</loc>
    <lastmod>2026-09-02T22:01:05+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>Teva’s TEV-408 Meets Primary Endpoint in Phase 2a Celiac Study</news:title>
      <news:keywords>Teva</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/2392ceaa-b1f3-44a8-bd7e-4c775053e093</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/evotec-plectonic-research-collaboration-t-cell-engager-solid-tumors</loc>
    <lastmod>2026-09-02T13:41:13+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>Evotec Partners With Plectonic to Advance T Cell Engager Platform</news:title>
      <news:keywords>Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/2a44d9e7-a3fb-40eb-a603-11aff3b65cf7/1ce08868-891a-4be1-9a53-231991e8178c.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/nicox-extends-cash-runway-q1-2028-ncx-470-pdufa</loc>
    <lastmod>2026-09-02T13:39:46+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>Nicox Extends Cash Runway to Q1 2028 Ahead of NCX 470 PDUFA Date</news:title>
      <news:keywords>Nicox</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/2a44d9e7-a3fb-40eb-a603-11aff3b65cf7/7ccbb5cb-0d59-4f5e-9484-8c5a9cc5da57.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/india-glycols-demerges-biopharma-ennature-bio-pharma</loc>
    <lastmod>2026-09-03T10:32:48+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>India Glycols Spins Off Biopharma Unit as Ennature Bio Pharma</news:title>
      <news:keywords>Biopharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/c50fdc99-abaf-4b13-a44a-995a9fc85710/d3b8a6b2-7814-4f7d-8116-392ef629c0bc.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-cber-ngs-workshop-adventitious-agent-detection-biologics-2026</loc>
    <lastmod>2026-09-02T12:43:26+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>FDA CBER Convenes NGS Workshop on Biologics Detection Standards</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/c50fdc99-abaf-4b13-a44a-995a9fc85710/a7f63bff-764e-4e14-9d50-9aabe626f726.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/atyr-pharma-fda-protocol-response-efzofitimod-phase-3-sarcoidosis-2026</loc>
    <lastmod>2026-09-02T12:43:28+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>aTyr Expects FDA Response on Phase 3 Sarcoidosis Study</news:title>
      <news:keywords>aTyr</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/132f33f3-c7e8-4d5b-abb0-040fb069a239/a216f6d4-6263-454d-859e-0bed167cc9fc.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/telix-bipass-enrollment-complete-fda-nda-pathway-68ga-psma-pet</loc>
    <lastmod>2026-09-02T12:43:28+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T00:00:00+05:30</news:publication_date>
      <news:title>Telix Completes BiPASS Enrollment, Secures FDA NDA Path</news:title>
      <news:keywords>Telix Pharmaceuticals</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png</image:loc>
    </image:image>
  </url>
</urlset>